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ABSTRACT
Objectives To compare the performance of the new
2016 American College of Rheumatology (ACR)-
European League Against Rheumatism (EULAR)
classiﬁcation criteria for primary Sjögren’s syndrome (SS)
with 1999 revised Japanese Ministry of Health criteria
for diagnosis of SS ( JPN), 2002 American-European
Consensus Group classiﬁcation criteria for SS (AECG) and
2012 ACR classiﬁcation criteria for SS (ACR) in Japanese
patients.
Methods The study subjects were 499 patients with
primary SS (pSS) or suspected pSS who were followed
up in June 2012 at 10 hospitals in Japan. All patients
had been assessed for all four criteria of JPN (pathology,
oral, ocular, anti-SS-A/SS-B antibodies). The clinical
diagnosis by the physician in charge was set as the ‘gold
standard’.
Results pSS was diagnosed in 302 patients and ruled
out in 197 patients by the physician in charge. The
sensitivity of the ACR-EULAR criteria in the diagnosis of
pSS (95.4%) was higher than those of the JPN, AECG
and ACR (82.1%, 89.4% and 79.1%, respectively),
while the speciﬁcity of the ACR-EULAR (72.1%) was
lower than those of the three sets (90.9%, 84.3% and
84.8%, respectively). The differences of sensitivities and
speciﬁcities between the ACR-EULAR and other three
sets of criteria were statistically signiﬁcant (p<0.001).
Eight out of 302 patients with pSS and 11 cases out of
197 non-pSS cases satisﬁed only the ACR-EULAR
criteria, compared with none of the other three sets.
Conclusions The ACR-EULAR criteria had signiﬁcantly
higher sensitivity and lower speciﬁcity in diagnosis of
pSS, compared with the currently available three sets of
criteria.
INTRODUCTION
Sjögren’s syndrome (SS) is an autoimmune disease
that affects mainly exocrine glands including the
salivary and lacrimal glands, and is often associated
with extraglandular manifestations, such as intersti-
tial lung and kidney diseases, and neurological,
haematological and musculoskeletal involvements.1
It is characterised by lymphocytic inﬁltration into
the exocrine glands and other organs, leading to
dry mouth, dry eyes and various extraglandular
symptoms. SS is subcategorised into primary SS
(pSS) which is not associated with other well
deﬁned connective tissue diseases (CTDs), and sec-
ondary SS which is associated with other well
deﬁned CTDs.2
In Japan, the revised criteria for the diagnosis of
SS proposed by the Japanese Ministry of Health
( JPN) (1999),3 as well as the American-European
Consensus Group classiﬁcation criteria for SS
(AECG) (2002)2 have been used commonly in both
daily clinical practice and clinical studies in this
decade. In 2012, the American College of
Rheumatology (ACR) published the 2012 ACR
classiﬁcation criteria for SS, which were proposed
by the Sjögren’s International Collaborative Clinical
Alliance (SICCA).4 These three sets of criteria have
also been applied for the diagnosis or classiﬁcation
of SS in Japan in the last 3 years. We previously
analysed 694 Japanese patients with SS or sus-
pected SS, and showed that the sensitivities of JPN,
AECG and ACR in the diagnosis of SS were
79.6%, 78.6% and 77.5%, respectively, with
respective speciﬁcities of 90.4%, 90.4% and
83.5%, when considering the clinical diagnosis as
the ‘gold standard’.5 We concluded in that study
the superiority of the JPN criteria in the diagnosis
of SS in Japanese patients compared with the ACR
and AECG criteria.5
Recently the 2016 new ACR-European League
Against Rheumatism (EULAR) classiﬁcation criteria
for pSS (ACR-EULAR) were published.6 7
Investigators from the SICCA team and the EULAR
Sjögren’s Task Force formed the International SS
Criteria Working Group to develop this single set
of classiﬁcation criteria that combined features of
the ACR and AECG criteria, based on method-
ology consistent with the current ACR and EULAR
guidelines.6 7 The working group adopted the
methodology based on both data and expert clini-
cal judgement, and ﬁnally deﬁned the new classiﬁ-
cation criteria comprising ﬁve objective tests or
items, and a total score of ≥4 as the cut-off for the
diagnosis of pSS. The total score is derived from
the sum of the weights assigned to each positive
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test or item as follows: focal lymphocytic sialadenitis in labial
salivary gland with Focus Score (FS) of ≥1 (based on number of
foci/4 mm2) and positive anti-SS-A/Ro serology with the highest
weights (3 for each positive test), and Ocular Staining Score
(OSS) of ≥5 (or Van Bijsterveld Score of ≥4) on at least one eye,
Schirmer’s test of ≤5 mm/5 min on at least one eye, and
unstimulated whole saliva (UWS) ﬂow rate of ≤0.1 mL/min with
a weight of 1 for each positive test.6 7
Comparison of the above four sets of criteria (table 1) shows
certain differences in the adopted items. In addition to the
adopted items, the purpose of these criteria sets also differs.
Importantly, the JPN criteria were formulated for the diagnosis
of SS as the diagnostic criteria, while other three sets of criteria
(the ACR-EULAR, AECG and ACR criteria) were formulated
for research purposes as the classiﬁcation criteria. The purpose
of the present study was to compare the performance of the
new ACR-EULAR criteria with the former sets of criteria, such
as the JPN, AECG and ACR criteria in Japanese patients.
PATIENTS AND METHODS
Study population
The study subjects were 499 patients (38 men and 461 women)
with the diagnosis of pSS or suspected pSS, who had been
checked for all four criteria of the JPN (pathology, oral, ocular,
anti SS-A/Ro and SS-B/La antibody), and were followed up in
June 2012 at 10 hospitals across Japan (Kanazawa Medical
University Hospital, Nagasaki University Hospital, Hyogo
Medical University Hospital, Keio University Hospital, Tokyo
Women’s Medical University Hospital, Tsurumi University
Hospital, Kyushu University Hospital, University of
Occupational and Environmental Health Hospital, Kyoto
University Hospital, and University of Tsukuba Hospital), which
form parts of the Research Team for Autoimmune Diseases, The
Research Program for Intractable Disease of the Japan Ministry
of Health, Labor and Welfare (MHLW).
Data collection and analysis
We collected clinical data through a questionnaire from the
above 10 hospitals. We retrospectively examined the clinical
diagnosis by the physician in charge, satisfaction of
ACR-EULAR, JPN, AECG and ACR criteria. Because the OSS
adopted in the ACR-EULAR and ACR criteria is not commonly
performed in Japan, we regarded patients with Van Bijsterveld
Score ≥4 in the Rose Bengal test, lissamine green test or ﬂuores-
cein staining test to have satisﬁed OSS in the ACR-EULAR cri-
teria, and patients who had positive Rose Bengal or lissamine
green test (Van Bijsterveld Score ≥3) or ﬂuorescein staining test
to have satisﬁed OSS in the ACR criteria. Similarly, because
numerous cases (116/499 cases) lacked results of the UWS,
which was not adopted in the JPN criteria,3 we regarded
patients who had UWS ≤0.1 mL/min, gum test ≤10 mL/10 min
or Saxon test ≤2 g/2 min to have satisﬁed low salivary volume
in the ACR-EULAR and AECG criteria.
Moreover, we performed the subanalysis using 383 cases who
were examined for UWS, excluding 116 cases who lacked
results of the UWS mentioned above. We examined satisfaction
for each criteria set more strictly in this subanalysis than in
whole analysis of 499 cases. For salivary volume, we regarded
patients who had gum test ≤10 mL/10 min or Saxon test ≤2 g/2
min to have satisﬁed decreased salivary volume in JPN criteria,
while UWS ≤0.1 mL/min in the ACR-EULAR and AECG cri-
teria. For ocular staining, we regarded patients with Van
Bijsterveld Score ≥3 in the Rose Bengal test, lissamine green test
or ﬂuorescein staining test, and/or positive ﬂuorescein staining
test to have satisﬁed positive ocular staining in JPN and ACR
criteria, while Van Bijsterveld Score ≥4 in AECG and
ACR-EULAR criteria.
We considered the clinical diagnosis by the physician in
charge as the ‘gold standard’ for the diagnosis of pSS in this
study. In all cases, the diagnosis established by the physician in
charge was based on clinical ﬁndings, laboratory and serological
tests of blood and saliva samples, sialography, scintigraphy, and
histopathological examination of biopsy material. We regarded
the clinical diagnosis by the physician in charge to be appropri-
ate for the ‘gold standard’, because the clinical diagnosis was
decided by senior and experienced clinicians belonging to 10
hospitals which form parts of the Research Team for
Autoimmune Diseases, The Research Program for Intractable
Disease of the Japan MHLW described above. We compared the
sensitivity and speciﬁcity between the ACR-EULAR, JPN,
AECG and ACR criteria in the diagnosis of pSS.
Statistical analysis
The differences of sensitivities and speciﬁcities between all pos-
sible pairs of the four sets of criteria were evaluated using the
McNemar’s test and the Newcombe’s square-and-add method.
A p value <0.05 denoted the presence of a statistically signiﬁ-
cant difference.
RESULTS
Diagnosis of pSS and denial of pSS
None of the 499 patients had other well deﬁned CTDs. pSS was
diagnosed in 302 patients, whereas pSS was excluded in 197
Table 1 Comparison of items adopted in the 2016 ACR-EULAR,
JPN, AECG and ACR criteria
Items ACR-EULAR JPN AECG ACR
Ocular symptoms Not adopted Not
adopted
Adopted Not
adopted
Oral symptoms Not adopted Not
adopted
Adopted Not
adopted
Ocular signs
Schirmer’s test Adopted (1 point) Adopted Adopted Not
adopted
Ocular staining Adopted (1 point) Adopted Adopted Adopted
Labial salivary gland
biopsy
Adopted (3 points) Adopted Adopted Adopted
Salivary gland involvements
Salivary secretion Adopted (1 point) Adopted Adopted Not
adopted
Sialography Not adopted Adopted Adopted Not
adopted
Scintigraphy Not adopted Adopted Adopted Not
adopted
Autoantibodies
SS-A/Ro Adopted (3 points) Adopted Adopted Adopted
SS-B/La Not adopted Adopted Adopted Adopted
ANA Not adopted Not
adopted
Not
adopted
Adopted
RF Not adopted Not
adopted
Not
adopted
Adopted
ACR, American College of Rheumatology ACR criteria for SS; ACR-EULAR, American
College of Rheumatology (ACR)-European League Against Rheumatism (EULAR)
classification criteria for pSS; AECG, The American-European Consensus Group
classification criteria for SS; ANA, antinuclear antibody; JPN, The revised Japanese
Ministry of Health criteria for the diagnosis of SS; pSS, primary SS; RF, rheumatoid factor;
SS, Sjögren’s syndrome; SS-A/Ro, anti-SS-A/Ro antibody; SS-B/La, anti-SS-B/La antibody.
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patients by the physician in charge, and these judgements were
considered as the ‘gold standard’ in the present study. For suba-
nalysis using 383 cases that were examined for UWS, pSS was
diagnosed in 203 patients, while pSS was excluded in 180
patients based on clinical judgements.
Sensitivity and speciﬁcity in diagnosis of pSS by different
sets of criteria
For all the 499 patients, the sensitivities of the ACR-EULAR,
JPN, AECG and ACR criteria in the diagnosis of pSS were
95.4% (95% CI 93.0% to 97.1%), 82.1% (79.6% to 84.1%),
89.4% (86.8% to 91.6%) and 79.1% (76.2% to 81.6%),
respectively, considering the diagnosis by the physician in charge
as the ‘gold standard’ (table 2). The respective speciﬁcities were
72.1% (68.4% to 74.7%), 90.9% (87.0% to 93.8%), 84.3%
(80.2% to 87.6%) and 84.8% (80.3% to 88.5%) (table 2).
For subanalysis using 383 cases that were examined for
UWS, the sensitivities of the ACR-EULAR, JPN, AECG and
ACR criteria in the diagnosis of pSS were 94.1% (90.8% to
96.4%), 74.9% (71.3% to 77.6%), 85.7% (82.1% to 88.7%)
and 79.8% (75.8% to 83.2%), respectively. The respective spe-
ciﬁcities were 76.7% (73.0% to 79.3%), 90.6% (86.5% to
93.7%), 86.1% (82.0% to 89.4%) and 81.1% (76.6% to
85.0%) (table 2).
The sensitivity of the ACR-EULAR criteria was statistically sig-
niﬁcantly higher than those of other three sets of criteria in
both whole analysis and subanalysis (p<0.001) (table 3). The
speciﬁcity of the ACR-EULAR criteria was statistically signiﬁ-
cantly lower than those of other three sets of criteria in whole
analysis (p<0.001) (table 3). Although the speciﬁcity of the
ACR-EULAR criteria was statistically signiﬁcantly lower than
those of the JPN and AECG criteria in subanalysis (p<0.001),
the difference between the ACR-EULAR and ACR criteria was
not statistically signiﬁcant (p=0.117) (table 3).
These ﬁndings indicate that the ACR-EULAR criteria have
higher sensitivity and lower speciﬁcity in the diagnosis of pSS,
compared with the JPN, AECG and ACR in both whole analysis
and subanalysis.
Agreement of ACR-EULAR criteria with the other three sets
of criteria
Table 4 shows the satisfaction for these four sets of criteria in
each case. The data showed that the ACR-EULAR criteria were
satisﬁed by much more cases than the other three sets of criteria
for both pSS (288 cases) and non-pSS (55 cases) groups. Many
pSS (220/302 cases, 72.8%) satisﬁed all four sets of criteria,
while many non-pSS (135/197 cases, 68.5%) satisﬁed none of
four sets of criteria (table 4). Although 8 non-pSS cases satisﬁed
all four sets of criteria, 11 patients with pSS did not satisfy any
set of criteria (table 4). There was no case that satisﬁed all the
other three sets of criteria except for the ACR-EULAR criteria
among both pSS and non-pSS groups (table 4).
Importantly, 8 out of the 302 patients with pSS diagnosed by
the physician in charge and 11 cases out of the 197 clinically
non-pSS cases satisﬁed only the ACR-EULAR criteria, compared
with none of the other three sets of criteria. These 19 cases
explained the low agreement between the ACR-EULAR criteria
and the other three sets of criteria. Further analysis of positivity
for each item adopted in the ACR-EULAR criteria among the 8
patients with pSS who satisﬁed only the ACR-EULAR criteria
indicated that they had positive FS (62.5%, 5/8 cases) or posi-
tive SS-A/Ro (37.5%, 3/8 cases), together with decreased saliv-
ary (87.5%, 7/8 cases) or lacrimal (12.5%, 1/8 cases) secretion,
resulting in a total score of 4 in these 8 patients (ﬁgure 1A).
The 11 non-pSS cases who satisﬁed only the ACR-EULAR cri-
teria had positive FS (54.5%, 6/11 cases) or positive SS-A/Ro
(45.5%, 5/11 cases), together with decreased salivary secretion
(100%, 11/11 cases), resulting in a total score of 4 in these 11
cases (ﬁgure 1B).
Considered together, the above analyses suggest that judge-
ment by the ACR-EULAR criteria for both diagnosis and exclu-
sion of pSS was different from those by the JPN, AECG and
ACR criteria (table 4).
DISCUSSION
In the present study, we compared the sensitivity and speciﬁcity
of the 2016 ACR-EULAR criteria for pSS with those of the
JPN, AECG and ACR criteria, for the diagnosis of pSS using
clinical data of 499 Japanese patients with pSS or suspected
pSS. The results showed clearly that the 2016 ACR-EULAR cri-
teria had higher sensitivity and lower speciﬁcity in the diagnosis
of pSS, compared with the other three sets of criteria in both
whole analysis (n=499) and subanalysis (n=383) using cases
that were examined for UWS. Moreover, the degree of agree-
ment of the ACR-EULAR criteria with the three sets of criteria
for both diagnosis and exclusion of pSS was low. These results
are different from those reported in a recent study by Shiboski
et al,6 7 which showed high sensitivity (96%, 95% CI 92% to
98%) and speciﬁcity (95%, 95% CI 92% to 97%) for the
ACR-EULAR criteria and high agreement rate with both AECG
Table 2 Sensitivity and specificity for the diagnosis of pSS by the four sets of criteria
Analysis Criteria sets Diagnosis by the physician in charge as the ‘gold standard’
Sensitivity (%) 95% CI Specificity (%) 95% CI
Whole
n=499
ACR-EULAR 95.4 (288/302) 93.0 to 97.1 72.1 (142/197) 68.4 to 74.7
JPN 82.1 (248/302) 79.6 to 84.1 90.9 (179/197) 87.0 to 93.8
AECG 89.4 (270/302) 86.8 to 91.6 84.3 (166/197) 80.2 to 87.6
ACR 79.1 (239/302) 76.2 to 81.6 84.8 (167/197) 80.3 to 88.5
Subanalysis
n=383
ACR-EULAR 94.1 (191/203) 90.8 to 96.4 76.7 (138/180) 73.0 to 79.3
JPN 74.9 (152/203) 71.3 to 77.6 90.6 (163/180) 86.5 to 93.7
AECG 85.7 (174/203) 82.1 to 88.7 86.1 (155/180) 82.0 to 89.4
ACR 79.8 (162/203) 75.8 to 83.2 81.1 (146/180) 76.6 to 85.0
Of the 499 enrolled patients, pSS was diagnosed in 302 patients, whereas pSS was excluded in 197 patients by the physician in charge. For subanalysis using 383 cases that were
examined for unstimulated whole saliva (UWS), pSS was diagnosed in 203 patients, while pSS was excluded in 180 patients based on clinical judgements.
ACR-EULAR, American College of Rheumatology (ACR)-European League Against Rheumatism (EULAR) classification criteria for pSS; AECG, American-European Consensus Group
classification criteria for SS; JPN, The revised Japanese Ministry of Health criteria for the diagnosis of SS; pSS, primary SS; SS, Sjögren’s syndrome.
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(κ coefﬁcient: 0.91) and ACR criteria (κ coefﬁcient: 0.82).
These disagreements seem to be somewhat related to our 8
patients with pSS and 11 non-pSS cases who did not satisfy any
of the JPN, AECG and ACR criteria, while they satisﬁed only
the ACR-EULAR criteria. Among these 19 cases, 11 non-pSS
cases had positive FS (6/11 cases) or positive anti-SS-A/Ro (5/11
cases), and decreased salivary volume (11/11 cases). These 11
non-pSS cases might cause the low speciﬁcity of the
ACR-EULAR criteria. However, one has to pay enough attention
to the adopted methods for assessment of salivary volume in
this study. As mentioned in the Patients and methods section,
we regarded patients with UWS ≤0.1 mL/min, gum test
≤10 mL/10 min or Saxon test ≤2 g/2 min to have satisﬁed
decreased salivary volume in the ACR-EULAR and AECG cri-
teria, because numerous cases (116/499 cases) lacked the results
of UWS, which was not adopted in the JPN criteria.3
Importantly, 6 out of 11 non-pSS cases who satisﬁed only the
ACR-EULAR criteria, were considered to have decreased saliv-
ary volume based on the gum and/or Saxon test instead of UWS
(data not shown). These six cases might explain the low speciﬁ-
city of the ACR-EULAR criteria in the present study. Actually, in
the subanalysis of 383 cases that were examined for UWS, the
speciﬁcity (76.7%) of the ACR-EULAR criteria was higher than
in the whole analysis (72.1%). On the other hand, eight patients
with pSS who satisﬁed only the ACR-EULAR criteria but none
of other three sets of criteria might cause the high sensitivity of
the ACR-EULAR criteria. These eight patients with pSS had
positive FS (5/8 cases) or positive anti-SS-A/Ro (3/8 cases),
accompanied with decreased salivary (7/8 cases) or lacrimal (1/8
cases) volume. Collectively, these 19 cases (8 patients with pSS
and 11 non-pSS cases) that satisﬁed only the ACR-EULAR cri-
teria but none of other three sets of criteria seem to lead to the
disagreement between the ACR-EULAR criteria and other three
sets of criteria. All of these 19 cases had positive FS (11/19
cases) or positive anti-SS-A/Ro (8/19 cases) accompanied by
decreased salivary (18/19 cases) or lacrimal (1/19 cases) volume.
Thus these 19 patients, even including clinically judged 11
non-pSS cases, seem to have a high probability of suffering from
‘true pSS’. This means that the ACR-EULAR criteria might
allow to correctly select patients with pSS who are misclassiﬁed
by other criteria sets. Importantly, the highest sensitivity of the
ACR-EULAR criteria might offer some advantages considering
that more patients with true pSS could be selected for clinical
and therapeutic trials. However, on the other hand, the lowest
Table 3 Differences of the sensitivities and specificities (with 95% CI) for the diagnosis of pSS among the four sets of criteria
Competitor JPN AECG ACR
Whole n=499
Sensitivities ACR-EULAR 13.2 (9.2 to 17.7) p<0.001 6.0 (3.0 to 9.4) p<0.001 16.2 (12.2 to 20.7) p<0.001
JPN – −7.3 (−11.8 to −2.9) p=0.001 3.0 (−0.3 to 6.4) p=0.072
AECG – – 10.3 (5.6 to 15.1) p<0.001
Specificities ACR-EULAR −18.8 (−24.7 to −13.1) p<0.001 −12.2 (−17.2 to −7.3) p<0.001 −12.7 (−18.6 to −6.8) p<0.001
JPN – 6.6 (0.8 to 12.5) p=0.024 6.1 (2.4 to 10.3) p=0.001
AECG – – 0.0 (−6.9 to 5.9) p=0.873
Subanalysis n=383
Sensitivities ACR-EULAR 19.2 (13.7 to 25.2) p<0.001 8.4 (4.3 to 13.1) p<0.001 14.3 (9.6 to 19.6) p<0.001
JPN – −10.8 (−17.3 to −4.4) p=0.001 −4.9 (−10.2 to 0.3) p=0.059
AECG – – 5.9 (−0.3 to 12.1) p=0.058
Specificities ACR-EULAR −13.9 (−19.6 to −8.6) p<0.001 −9.4 (−14.4 to −4.8) p<0.001 −4.4 (−10.2 to 1.2) p=0.117
JPN – 4.4 (−1.5 to 10.5) p=0.131 9.4 (4.9 to 14.5) p<0.001
AECG – – 5.0 (−1.6 to 11.6) p=0.128
Of the 499 enrolled patients, pSS was diagnosed in 302 patients, whereas pSS was excluded in 197 patients by the physician in charge. For subanalysis using 383 cases that were
examined for unstimulated whole saliva (UWS), pSS was diagnosed in 203 patients, while pSS was excluded in 180 patients based on clinical judgements.
The p values and confidence limits were computed by the McNemar’s test and the Newcombe’s square-and-add method.
–, not examined; ACR-EULAR, American College of Rheumatology (ACR)-European League Against Rheumatism (EULAR) classification criteria for pSS; AECG, American-European
Consensus Group classification criteria for SS; JPN, The revised Japanese Ministry of Health criteria for the diagnosis of SS; pSS, primary SS; SS, Sjögren’s syndrome.
Table 4 Satisfaction of the ACR-EULAR, JPN, AECG and ACR criteria
in clinically diagnosed pSS and non-pSS cases
Cases
ACR-EULAR JPN AECG ACRpSS non-pSS
220 8 O O O O
14 0 O O O X
11 8 O O X O
7 3 O X O O
0 0 X O O O
0 1 O O X X
27 19 O X O X
1 5 O X X O
2 0 X O O X
0 1 X O X O
0 0 X X O O
8 11 O X X X
1 0 X O X X
0 1 X X O X
0 5 X X X O
11 135 X X X X
Total 302 197 pSS 288 248 270 239
non-pSS 55 18 31 30
Total numbers of cases that satisfied each criteria set
Of the 499 enrolled patients, pSS was diagnosed in 302 patients, whereas pSS was
excluded in 197 patients by the physician in charge.
ACR-EULAR, American College of Rheumatology (ACR)-European League Against
Rheumatism (EULAR) classification criteria for pSS; AECG, American-European
Consensus Group classification criteria for SS; JPN, The revised Japanese Ministry of
Health criteria for the diagnosis of SS; O, satisfaction; pSS, primary SS; SS, Sjögren’s
syndrome; X, non-satisfaction.
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speciﬁcity of the ACR-EULAR criteria for Japanese patients with
pSS was conﬁrmed in both whole analysis and subanalysis using
383 cases that were examined for UWS, whereas the speciﬁcity
was higher (76.7%) in subanalysis than in whole analysis
(72.1%). A high speciﬁcity is the most critical aspect because
this prevents subjects without pSS from entering clinical studies
or trials. Therefore, if we apply the ACR-EULAR criteria to
Japanese clinical studies targeted on pSS, we have to pay
enough attention to this low speciﬁcity.
The 2016 ACR-EULAR criteria focused on pSS only but not
on secondary SS, which is associated with other well deﬁned
CTDs.6 7 However, the International SS Criteria Working
Group indicated that these criteria could also be applicable for
secondary SS, and recommended further studies for secondary
SS to conﬁrm this.6 7 Thus, we also need to compare the per-
formance of these four sets of criteria, including the
ACR-EULAR, in the diagnosis of secondary SS because we tar-
geted only patients with pSS or suspected pSS who were free of
other CTDs.
The present study has certain limitations. First, we applied
the diagnosis by the physician in charge as the ‘gold standard’.
However, it is better to decide disease case or non-case status by
expert clinical judgement based on clinical vignettes for the
‘gold standard’ diagnosis, which has been employed by newly
developed classiﬁcation criteria, such as the 2016 ACR-EULAR
criteria for pSS6 7 and the proposed new classiﬁcation criteria
for systemic lupus erythematosus (SLE) by the Systemic Lupus
International Collaborating Clinics.8 Moreover, since this study
was entirely carried out in Japan, it might be predicted that the
physicians who commonly used JPN criteria could be strongly
inﬂuenced in their mind by this conceptual habit when they
clinically deﬁned cases as having pSS or not. Second, the
methods adopted for ocular staining and salivary tests varied
among the participating institutions, forcing us to modify
certain items in some criteria as described in the Patients and
methods section. For these reasons, we need a more sophisti-
cated validation cohort study, using expert clinical judgement
based on clinical vignettes as the ‘gold standard’ and integrated
methodology for ocular staining and salivary measurement that
ﬁts completely with the items adopted in the criteria.
In addition to the classiﬁcation criteria for clinical studies, we
also need diagnostic criteria for daily clinical practice. The JPN
criteria were established for the diagnosis of SS including both
pSS and secondary SS, and are always used in daily clinical
Figure 1 Satisfaction for each item adopted in the American College of Rheumatology (ACR)-European League Against Rheumatism (EULAR)
classiﬁcation criteria for pSS (ACR-EULAR) among 19 cases that satisﬁed only the ACR-EULAR criteria. (A) Eight patients with primary Sjögren’s
syndrome (pSS) who only satisﬁed the ACR-EULAR criteria had positive Focus Score (FS) (62.5%, 5/8 cases) or pSS-A/Ro (37.5%, 3/8 cases), together
with decreased salivary (87.5%, 7/8 cases) or lacrimal (12.5%, 1/8 cases) secretion, resulting in Total Score 4. (B) Eleven non-pSS cases who only
satisﬁed the ACR-EULAR criteria had positive FS (54.5%, 6/11 cases) or positive SS-A/Ro (45.5%, 5/11 cases), together with decreased salivary
secretion (100%, 11/11 cases), resulting in Total Score 4. White boxes: non-satisfaction, shadowed boxes: satisfaction (dark shadow: 3 points, light
shadow: 1 point). FS-LSG, FS ≥1 foci/4 mm2 in labial salivary gland; SS-A/Ro, positive anti-SS-A/Ro antibody; Ocular staining, Van Bijsterveld Score
≥4 in Rose Bengal test, lissamine green test or ﬂuorescein staining test; Schirmer, Schirmer’s test ≤5 mm/5 min; Saliva, unstimulated whole saliva
(UWS) ≤0.1 mL/min, gum test ≤10 mL/10 min or Saxon test ≤2 g/2 min.
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practice in Japan. Moreover, we reported previously that the
JPN criteria had the highest sensitivity (79.6%) and speciﬁcity
(90.4%) for all SS, including both primary and secondary SS,
among the JPN, AECG and ACR criteria in Japan.5 However,
the JPN criteria adopt sialography, scintigraphy, and gum and
Saxon tests for assessment of salivary volume, which are neither
adopted in the 2016 ACR-EULAR nor ACR criteria.3 4 6 7
Furthermore, the JPN criteria use a different cut-off value for
ocular staining (Van Bijsterveld Score ≥3) from those used by
the ACR-EULAR (Van Bijsterveld Score ≥4 or OSS ≥5), AECG
(Van Bijsterveld Score ≥4) and ACR criteria (OSS ≥3).2–4 6 7
Thus, we need to examine the performance of the JPN criteria
using alternative items that are adopted in the ACR-EULAR cri-
teria, such as UWS for gum and Saxon tests, and Van Bijsterveld
Score ≥4 or OSS ≥5 for Van Bijsterveld Score ≥3 by a prospect-
ive validation cohort study in the near future.
In conclusion, although this study has certain limitations, the
results showed that the ACR-EULAR criteria have higher sensi-
tivity and lower speciﬁcity in the diagnosis of pSS, compared
with the JPN, AECG and ACR criteria. Furthermore, the degree
of agreement of the ACR-EULAR criteria with the other three
sets of criteria for the diagnosis and denial of pSS was low.
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